We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 250

US pharma companies under increasing legislative pressure, key EU SPC decision and much more in July’s life sciences IP round-up
  • IAM
  • USA
  • August 9 2018

In this month’s round-up of patent news from the life sciences, we report on the latest blow to the St Regis Mohawks’ attempt shield their Restasis

The Latest: FTC to Look Closely at Competition between Biologics and Biosimilars and Patent Protection Strategies of Branded Manufacturers
  • McDermott Will & Emery
  • USA
  • July 24 2018

On July 18, 2018, US Food and Drug Administration (FDA) Commissioner Scott Gottlieb delivered a speech at The Brookings Institution in Washington, DC

FTC Says Hatch-Waxman Suits Not Immune from Antitrust Scrutiny
  • Vinson & Elkins LLP
  • USA
  • June 26 2018

The Federal Trade Commission (“FTC”) has sought permission to file an amicus brief in a pharmaceutical patent case, urging a district court to reject

Hatch-Waxman and BPCIA Developments in May 2018
  • Morrison & Foerster LLP
  • USA
  • June 6 2018

This month, we highlight significant developments in May 2018, including a stunning reverse payment decision at the FTC, draft guidance from the FDA

FDA Holds Public Meeting on Innovation in Drug Development and Accelerating Access to Generic Medicines
  • Arent Fox LLP
  • USA
  • July 20 2017

On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and Accelerating the access

Dietary Supplement Legal Update - June 2017
  • Porzio Bromberg & Newman PC
  • USA
  • June 13 2017

A variety of legal and regulatory challenges exist in the dietary supplement industry, including federal and state legislatures, agencies and courts

Reverse Payment PTAB Settlements in BioPharma?
  • Oblon
  • USA
  • July 28 2016

Print Anti-Competitive IPR Settlements for Orange Book Patents? The Patent Trial & Appeal Board (PTAB) has the power to terminate an Inter Partes

Senate Judiciary Introduces CREATES Act To Expedite Access To Affordable Drugs
  • Foley & Lardner LLP
  • USA
  • July 5 2016

Following months of public outcry and Congressional probes into significant drug price increases, the Senate Judiciary Committee introduced

Applying the Supreme Court’s decision in Actavis
  • King & Spalding LLP
  • USA
  • July 24 2013

In FTC v. Actavis, the Supreme Court held that “reverse payment” pharma patent settlements are not categorically immune from the antitrust laws even

Supreme Court reverses Eleventh Circuit’s AndroGel decision
  • Alston & Bird LLP
  • USA
  • July 17 2013

On June 17, 2013, the United States Supreme Court (in a split decision) held that settlements of pharmaceutical patent disputes where a patent holder